{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:16:02Z","timestamp":1790486162871,"version":"4.1.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s13311-022-01222-x","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T02:14:26Z","timestamp":1648520066000},"page":"874-884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8035-0200","authenticated-orcid":false,"given":"Chiara","family":"Briani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Visentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-022-01222-x_bib1","unstructured":"Latov N. Immune mechanisms, the role of complement, and related therapies in autoimmune neuropathies. Expert Rev Clin Immunol. 2021:1\u201313."},{"issue":"6","key":"10.1007\/s13311-022-01222-x_bib2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","article-title":"Safety and efficacy of eculizumab in Guillain-Barre syndrome: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Misawa","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-022-01222-x_bib3","doi-asserted-by":"crossref","unstructured":"Yamaguchi N, Misawa S, Sato Y, Nagashima K, Katayama K, Sekiguchi Y, et al. A prospective, multicenter, randomized phase II study to evaluate the efficacy and safety of Eeculizumab in patients with Guillain-Barre Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS). JMIR Res Protoc. 2016;5(4):e210.","DOI":"10.2196\/resprot.6610"},{"key":"10.1007\/s13311-022-01222-x_bib4","doi-asserted-by":"crossref","unstructured":"Querol L, Lleixa C. Novel immunological and therapeutic insights in Guillain-Barre syndrome and CIDP. Neurotherapeutics. 2021.","DOI":"10.1007\/s13311-021-01117-3"},{"issue":"11","key":"10.1007\/s13311-022-01222-x_bib5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"10.1007\/s13311-022-01222-x_bib6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1007\/s13311-022-01222-x_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology\u2013mode of action and clinical efficacy","volume":"11","author":"Lunemann","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1007\/s13311-022-01222-x_bib8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/jns.12455","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision","volume":"26","author":"Van den Bergh","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"10.1007\/s13311-022-01222-x_bib9","doi-asserted-by":"crossref","unstructured":"Briani C, Cocito D, Campagnolo M, Doneddu PE, Nobile-Orazio E. Update on therapy of chronic immune-mediated neuropathies. Neurol Sci. 2021.","DOI":"10.1007\/s10072-020-04998-y"},{"key":"10.1007\/s13311-022-01222-x_bib10","doi-asserted-by":"crossref","unstructured":"van Schaik IN, Mielke O, Bril V, van Geloven N, Hartung HP, Lewis RA, et al. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurol Neuroimmunol Neuroinflamm. 2019;6(5):e590.","DOI":"10.1212\/NXI.0000000000000590"},{"key":"10.1007\/s13311-022-01222-x_bib11","doi-asserted-by":"crossref","unstructured":"Cocito D, Grimaldi S, Paolasso I, Falcone Y, Antonini G, Benedetti L, et al. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol. 2011;18(12):1417\u201321.","DOI":"10.1111\/j.1468-1331.2011.03495.x"},{"key":"10.1007\/s13311-022-01222-x_bib12","doi-asserted-by":"crossref","unstructured":"Mahdi-Rogers M, Brassington R, Gunn AA, van Doorn PA, Hughes RA. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2017;5:CD003280.","DOI":"10.1002\/14651858.CD003280.pub5"},{"issue":"11","key":"10.1007\/s13311-022-01222-x_bib13","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1468-1331.2004.00911.x","article-title":"Rituximab-responsive CIDP","volume":"11","author":"Briani","year":"2004","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1007\/s13311-022-01222-x_bib14","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1136\/jnnp.2009.188912","article-title":"Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature","volume":"82","author":"Benedetti","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1007\/s13311-022-01222-x_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jns.12287","article-title":"Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases","volume":"23","author":"Roux","year":"2018","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"10.1007\/s13311-022-01222-x_bib16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.26804","article-title":"Rituximab in refractory chronic inflammatory demyelinating polyneuropathy","volume":"61","author":"Muley","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-022-01222-x_bib17","doi-asserted-by":"crossref","unstructured":"Hu J, Sun C, Lu J, Zhao C, Lin J. Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. J Neurol. 2021.","DOI":"10.1007\/s00415-021-10646-y"},{"key":"10.1007\/s13311-022-01222-x_bib18","doi-asserted-by":"crossref","unstructured":"Shimizu S, Iijima M, Fukami Y, Tamura N, Nakatochi M, Ando M, et al. Efficacy and safety of rituximab in refractory CIDP with or without IgG4 autoantibodies (RECIPE): Protocol for a double-blind, randomized, placebo-controlled clinical trial. JMIR Res Protoc. 2020;9(4):e17117.","DOI":"10.2196\/17117"},{"key":"10.1007\/s13311-022-01222-x_bib19","doi-asserted-by":"crossref","unstructured":"Mevorach D, Reiner I, Grau A, Ilan U, Berkun Y, Ta-Shma A, et al. Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation. Ann Neurol. 2016;80(5):708\u201317.","DOI":"10.1002\/ana.24770"},{"issue":"1","key":"10.1007\/s13311-022-01222-x_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2012-07-441857","article-title":"CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy","volume":"121","author":"Nevo","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1007\/s13311-022-01222-x_bib21","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1212\/WNL.0000000000001391","article-title":"Early-onset chronic axonal neuropathy, strokes, and hemolysis: inherited CD59 deficiency","volume":"84","author":"Haliloglu","year":"2015","journal-title":"Neurology"},{"issue":"10","key":"10.1007\/s13311-022-01222-x_bib22","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1007\/s13311-022-01222-x_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1007\/s13311-022-01222-x_bib24","doi-asserted-by":"crossref","unstructured":"Nelke C, Spatola M, Schroeter CB, Wiendl H, Lunemann JD. Neonatal Fc receptor-targeted therapies in neurology. Neurotherapeutics. 2022.","DOI":"10.1007\/s13311-021-01175-7"},{"issue":"8","key":"10.1007\/s13311-022-01222-x_bib25","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nri856","article-title":"Roles of Fc receptors in autoimmunity","volume":"2","author":"Takai","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1007\/s13311-022-01222-x_bib26","doi-asserted-by":"crossref","unstructured":"Zhang G, Bogdanova N, Gao T, Song JJ, Cragg MS, Glennie MJ, et al. Fcgamma receptor-mediated inflammation inhibits axon regeneration. PLoS One. 2014;9(2):e88703.","DOI":"10.1371\/journal.pone.0088703"},{"issue":"17","key":"10.1007\/s13311-022-01222-x_bib27","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1523\/JNEUROSCI.4926-14.2015","article-title":"Anti-Ganglioside antibodies induce nodal and axonal injury via Fcgamma receptor-mediated inflammation","volume":"35","author":"He","year":"2015","journal-title":"J Neurosci"},{"issue":"1","key":"10.1007\/s13311-022-01222-x_bib28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/187152809787582525","article-title":"Role of Fc Receptors as a therapeutic target","volume":"8","author":"Masuda","year":"2009","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1007\/s13311-022-01222-x_bib29","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3389\/fimmu.2019.00811","article-title":"Understanding Fc Receptor involvement in inflammatory diseases: From mechanisms to new therapeutic tools","volume":"10","author":"Ben Mkaddem","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1007\/s13311-022-01222-x_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13238-017-0473-8","article-title":"IgG Fc engineering to modulate antibody effector functions","volume":"9","author":"Wang","year":"2018","journal-title":"Protein Cell"},{"issue":"11","key":"10.1007\/s13311-022-01222-x_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0345-9","article-title":"Boosting therapeutic potency of antibodies by taming Fc domain functions","volume":"51","author":"Kang","year":"2019","journal-title":"Exp Mol Med"},{"key":"10.1007\/s13311-022-01222-x_bib32","doi-asserted-by":"crossref","unstructured":"Uncini A, Mathis S, Vallat JM. New classification of autoimmune neuropathies based on target antigens and involved domains of myelinated fibres. J Neurol Neurosurg Psychiatry. 2021.","DOI":"10.1136\/jnnp-2021-326889"},{"issue":"5","key":"10.1007\/s13311-022-01222-x_bib33","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/WCO.0000000000000233","article-title":"Paranodal and other autoantibodies in chronic inflammatory neuropathies","volume":"28","author":"Querol","year":"2015","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"10.1007\/s13311-022-01222-x_bib34","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/jnnp-2021-326676","article-title":"Autoimmune nodopathies: treatable neuropathies beyond traditional classifications","volume":"92","author":"Querol","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1007\/s13311-022-01222-x_bib35","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1007\/s00415-020-10041-z","article-title":"Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera","volume":"267","author":"Delmont","year":"2020","journal-title":"J Neurol"},{"key":"10.1007\/s13311-022-01222-x_bib36","doi-asserted-by":"crossref","unstructured":"Cortese A, Lombardi R, Briani C, Callegari I, Benedetti L, Manganelli F, et al. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype. Neurol Neuroimmunol Neuroinflamm. 2020;7(1).","DOI":"10.1212\/NXI.0000000000000639"},{"key":"10.1007\/s13311-022-01222-x_bib37","doi-asserted-by":"crossref","unstructured":"Stengel H, Vural A, Brunder AM, Heinius A, Appeltshauser L, Fiebig B, et al. Anti-pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy. Neurol Neuroimmunol Neuroinflamm. 2019;6(5).","DOI":"10.1212\/NXI.0000000000000603"},{"key":"10.1007\/s13311-022-01222-x_bib38","doi-asserted-by":"crossref","unstructured":"Fels M, Fisse AL, Schwake C, Motte J, Athanasopoulos D, Gruter T, et al. Report of a fulminant anti-pan-neurofascin-associated neuropathy responsive to rituximab and bortezomib. J Peripher Nerv Syst. 2021.","DOI":"10.1111\/jns.12465"},{"issue":"4","key":"10.1007\/s13311-022-01222-x_bib39","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/brain\/awab014","article-title":"Antibodies to the Caspr1\/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"144","author":"Pascual-Goni","year":"2021","journal-title":"Brain"},{"issue":"9","key":"10.1007\/s13311-022-01222-x_bib40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrneurol.2017.84","article-title":"Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications","volume":"13","author":"Querol","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"10.1007\/s13311-022-01222-x_bib41","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/jnnp-2014-309916","article-title":"Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies","volume":"86","author":"Doppler","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1007\/s13311-022-01222-x_bib42","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.nmd.2016.10.008","article-title":"Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-Neurofascin 155 antibodies","volume":"27","author":"Vallat","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1007\/s13311-022-01222-x_bib43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/jnnp-2016-314895","article-title":"Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies","volume":"88","author":"Koike","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-022-01222-x_bib44","doi-asserted-by":"crossref","unstructured":"Dalakas MC. IgG4-mediated neurologic autoimmunities: Understanding the pathogenicity of IgG4, ineffectiveness of IVIg, and long-lasting benefits of anti-B cell therapies. Neurol Neuroimmunol Neuroinflamm. 2022;9(1).","DOI":"10.1212\/NXI.0000000000001116"},{"key":"10.1007\/s13311-022-01222-x_bib45","doi-asserted-by":"crossref","unstructured":"Martin-Aguilar L, Lleixa C, Pascual-Goni E, Caballero-Avila M, Martinez-Martinez L, Diaz-Manera J, et al. Clinical and laboratory features in anti-NF155 autoimmune nodopathy. Neurol Neuroimmunol Neuroinflamm. 2022;9(1).","DOI":"10.1212\/NXI.0000000000001129"},{"key":"10.1007\/s13311-022-01222-x_bib46","doi-asserted-by":"crossref","unstructured":"Scheibe F, Ostendorf L, Pruss H, Radbruch H, Aschman T, Hoffmann S, et al. Daratumumab for treatment-refractory antibody-mediated diseases in neurology. Eur J Neurol. 2022.","DOI":"10.1111\/ene.15266"},{"issue":"5","key":"10.1007\/s13311-022-01222-x_bib47","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/WCO.0000000000000605","article-title":"Multifocal motor neuropathy","volume":"31","author":"Beadon","year":"2018","journal-title":"Curr Opin Neurol"},{"issue":"7","key":"10.1007\/s13311-022-01222-x_bib48","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/jnnp-2013-305755","article-title":"Sensitivity and predictive value of anti-GM1\/galactocerebroside IgM antibodies in multifocal motor neuropathy","volume":"85","author":"Nobile-Orazio","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-022-01222-x_bib49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.intimp.2016.08.019","article-title":"Polyclonal IgM and IgA block in vitro complement deposition mediated by anti-ganglioside antibodies in autoimmune neuropathies","volume":"40","author":"Sudo","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"10.1007\/s13311-022-01222-x_bib50","doi-asserted-by":"crossref","unstructured":"Vlam L, Cats EA, Harschnitz O, Jansen MD, Piepers S, Veldink JH, et al. Complement activity is associated with disease severity in multifocal motor neuropathy. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e119.","DOI":"10.1212\/NXI.0000000000000119"},{"key":"10.1007\/s13311-022-01222-x_bib51","doi-asserted-by":"crossref","unstructured":"Harschnitz O, van den Berg LH, Johansen LE, Jansen MD, Kling S, Vieira de Sa R, et al. Autoantibody pathogenicity in a multifocal motor neuropathy induced pluripotent stem cell-derived model. Ann Neurol. 2016;80(1):71\u201388.","DOI":"10.1002\/ana.24680"},{"key":"10.1007\/s13311-022-01222-x_bib52","doi-asserted-by":"crossref","unstructured":"Budding K, Johansen LE, Van de Walle I, Dijkxhoorn K, de Zeeuw E, Bloemenkamp LM, et al. Anti-C2 antibody ARGX-117 inhibits complement in a disease model for multifocal motor neuropathy. Neurol Neuroimmunol Neuroinflamm. 2022;9(1).","DOI":"10.1212\/NXI.0000000000001107"},{"key":"10.1007\/s13311-022-01222-x_bib53","doi-asserted-by":"crossref","unstructured":"Joint Task Force of the E, the PNS. European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society\u2013first revision. J Peripher Nerv Syst. 2010;15(4):295\u2013301.","DOI":"10.1111\/j.1529-8027.2010.00290.x"},{"key":"10.1007\/s13311-022-01222-x_bib54","doi-asserted-by":"crossref","unstructured":"Keddie S, Eftimov F, van den Berg LH, Brassington R, de Haan RJ, van Schaik IN. Immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev. 2022;1:CD004429.","DOI":"10.1002\/14651858.CD004429.pub3"},{"issue":"15","key":"10.1007\/s13311-022-01222-x_bib55","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1212\/WNL.0b013e3181f735ce","article-title":"Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy","volume":"75","author":"Harbo","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01222-x_bib56","doi-asserted-by":"crossref","unstructured":"Umapathi T, Hughes RA, Nobile-Orazio E, Leger JM. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev. 2015(3):CD003217.","DOI":"10.1002\/14651858.CD003217.pub5"},{"issue":"4","key":"10.1007\/s13311-022-01222-x_bib57","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","article-title":"Treatment of IgM antibody associated polyneuropathies using rituximab","volume":"74","author":"Pestronk","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1007\/s13311-022-01222-x_bib58","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1212\/01.WNL.0000145706.04340.25","article-title":"Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg","volume":"63","author":"Ruegg","year":"2004","journal-title":"Neurology"},{"issue":"7","key":"10.1007\/s13311-022-01222-x_bib59","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.nmd.2009.04.013","article-title":"Beneficial effect of rituximab monotherapy in multifocal motor neuropathy","volume":"19","author":"Stieglbauer","year":"2009","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1007\/s13311-022-01222-x_bib60","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1529-8027.2010.00270.x","article-title":"An open-label trial of rituximab (Rituxan(R)) in multifocal motor neuropathy","volume":"15","author":"Chaudhry","year":"2010","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"10.1007\/s13311-022-01222-x_bib61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1529-8027.2011.00328.x","article-title":"An open label clinical trial of complement inhibition in multifocal motor neuropathy","volume":"16","author":"Fitzpatrick","year":"2011","journal-title":"J Peripher Nerv Syst"},{"issue":"11","key":"10.1007\/s13311-022-01222-x_bib62","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJM198009113031105","article-title":"Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin","volume":"303","author":"Latov","year":"1980","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1007\/s13311-022-01222-x_bib63","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/jns.12342","article-title":"Limitations in daily activities and general perception of quality of life: Long term follow-up in patients with anti-myelin-glycoprotein antibody polyneuropathy","volume":"24","author":"Campagnolo","year":"2019","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"10.1007\/s13311-022-01222-x_bib64","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jns.12197","article-title":"Determinants of health-related quality of life in anti-MAG neuropathy: a cross-sectional multicentre European study","volume":"22","author":"Delmont","year":"2017","journal-title":"J Peripher Nerv Syst"},{"issue":"Pt 4","key":"10.1007\/s13311-022-01222-x_bib65","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/brain\/123.4.710","article-title":"Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies","volume":"123","author":"Nobile-Orazio","year":"2000","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01222-x_bib66","doi-asserted-by":"crossref","unstructured":"Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2016;10:CD002827.","DOI":"10.1002\/14651858.CD002827.pub4"},{"issue":"3","key":"10.1007\/s13311-022-01222-x_bib67","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann Neurol"},{"issue":"24","key":"10.1007\/s13311-022-01222-x_bib68","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy","volume":"80","author":"Leger","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-022-01222-x_bib69","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1007\/s13311-022-01222-x_bib70","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/jnnp-2017-315736","article-title":"IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy","volume":"88","author":"Campagnolo","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1007\/s13311-022-01222-x_bib71","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/jnnp-2017-316715","article-title":"Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features","volume":"89","author":"Svahn","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-022-01222-x_bib72","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jns.2017.04.015","article-title":"Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy","volume":"377","author":"Gazzola","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-022-01222-x_bib73","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jns.2017.04.016","article-title":"Rituximab in anti-MAG neuropathy: More evidence for efficacy and more predictive factors","volume":"377","author":"Dalakas","year":"2017","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1007\/s13311-022-01222-x_bib74","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/mus.20386","article-title":"Worsening after rituximab treatment in anti-mag neuropathy","volume":"32","author":"Broglio","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-022-01222-x_bib75","unstructured":"Gironi M, Saresella M, Ceresa L, Calvo M, Ferrante P, Merli F, et al. Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with rituximab. Haematologica. 2006;91(6 Suppl):ECR17."},{"key":"10.1007\/s13311-022-01222-x_bib76","doi-asserted-by":"crossref","unstructured":"Noronha V, Fynan TM, Duffy T. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia. J Clin Oncol. 2006;24(1):e3.","DOI":"10.1200\/JCO.2005.04.6474"},{"issue":"1\u20132","key":"10.1007\/s13311-022-01222-x_bib77","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jns.2014.07.055","article-title":"Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy","volume":"345","author":"Sala","year":"2014","journal-title":"J Neurol Sci"},{"issue":"11","key":"10.1007\/s13311-022-01222-x_bib78","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","article-title":"Consensus treatment recommendations from the tenth International Workshop for Waldenstrom Macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1007\/s13311-022-01222-x_bib79","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/CND.0000000000000087","article-title":"Correlation of Changes in Gait Parameters, With Phenotype, Outcome Measures, and Electrodiagnostic Abnormalities in a Patient With Anti-MAG Neuropathy After Exacerbation and Improvement","volume":"17","author":"Vo","year":"2015","journal-title":"J Clin Neuromuscul Dis"},{"issue":"4","key":"10.1007\/s13311-022-01222-x_bib80","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/1744666X.2019.1562905","article-title":"Infusion-related reactions to rituximab: frequency, mechanisms and predictors","volume":"15","author":"Paul","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1007\/s13311-022-01222-x_bib81","doi-asserted-by":"crossref","unstructured":"Massa F, Zuppa A, Pesce G, Demichelis C, Bergamaschi M, Garnero M, et al. Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy. J Neurol Sci. 2020;413:116777.","DOI":"10.1016\/j.jns.2020.116777"},{"issue":"8","key":"10.1007\/s13311-022-01222-x_bib82","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrneurol.2014.117","article-title":"Diagnosis and treatment of chronic acquired demyelinating polyneuropathies","volume":"10","author":"Latov","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"10.1007\/s13311-022-01222-x_bib83","doi-asserted-by":"crossref","first-page":"E269","DOI":"10.1002\/ajh.26201","article-title":"Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials","volume":"96","author":"Morabito","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1007\/s13311-022-01222-x_bib84","doi-asserted-by":"crossref","first-page":"9679","DOI":"10.2147\/OTT.S268899","article-title":"Lights and shade of next-generation Pi3k inhibitors in chronic lymphocytic leukemia","volume":"13","author":"Visentin","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1007\/s13311-022-01222-x_bib85","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejca.2016.11.020","article-title":"Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients","volume":"72","author":"Visentin","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1007\/s13311-022-01222-x_bib86","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(16)30166-1","article-title":"Once-weekly ofatumumab in untreated or relapsed Waldenstrom's macroglobulinaemia: an open-label, single-arm, phase 2 study","volume":"4","author":"Furman","year":"2017","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1007\/s13311-022-01222-x_bib87","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1007\/s13311-022-01222-x_bib88","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000381524","article-title":"Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody","volume":"38","author":"Goede","year":"2015","journal-title":"Oncol Res Treat"},{"issue":"22","key":"10.1007\/s13311-022-01222-x_bib89","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"key":"10.1007\/s13311-022-01222-x_bib90","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-014-0058-4","article-title":"New antibody approaches to lymphoma therapy","volume":"7","author":"Suresh","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1007\/s13311-022-01222-x_bib91","doi-asserted-by":"crossref","unstructured":"Rakocevic G, Martinez-Outschoorn U, Dalakas MC. Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy. Neurol Neuroimmunol Neuroinflamm. 2018;5(4):e460.","DOI":"10.1212\/NXI.0000000000000460"},{"issue":"2","key":"10.1007\/s13311-022-01222-x_bib92","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ene.13838","article-title":"Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy","volume":"26","author":"Briani","year":"2019","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1007\/s13311-022-01222-x_bib93","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/jns.12405","article-title":"From pathogenesis to personalized treatments of neuropathies in hematological malignancies","volume":"25","author":"Briani","year":"2020","journal-title":"J Peripher Nerv Syst"},{"issue":"15","key":"10.1007\/s13311-022-01222-x_bib94","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1007\/s13311-022-01222-x_bib95","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1007\/s13311-022-01222-x_bib96","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/jnnp-2017-316689","article-title":"High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy","volume":"89","author":"Vos","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-022-01222-x_bib97","doi-asserted-by":"crossref","unstructured":"Castellani F, Visentin A, Campagnolo M, Salvalaggio A, Cacciavillani M, Candiotto C, et al. The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. Neurol Neuroimmunol Neuroinflamm. 2020;7(4).","DOI":"10.1212\/NXI.0000000000000720"},{"issue":"2","key":"10.1007\/s13311-022-01222-x_bib98","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"18","key":"10.1007\/s13311-022-01222-x_bib99","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"10.1007\/s13311-022-01222-x_bib100","unstructured":"Tam CS, Dimopoulos MA, Garcia-Sanz R, Trotman J, Opat S, Roberts AW, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2021."},{"issue":"23","key":"10.1007\/s13311-022-01222-x_bib101","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2020003010","article-title":"Zanubrutinib for the treatment of MYD88 wild-type Waldenstrom macroglobulinemia: a substudy of the phase 3 ASPEN trial","volume":"4","author":"Dimopoulos","year":"2020","journal-title":"Blood Adv"},{"issue":"34","key":"10.1007\/s13311-022-01222-x_bib102","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-022-01222-x_bib103","unstructured":"Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, et al. Venetoclax in previously treated Waldenstrom Macroglobulinemia. J Clin Oncol. 2021:JCO2101194."},{"issue":"10","key":"10.1007\/s13311-022-01222-x_bib104","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJM199003083221002","article-title":"Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy","volume":"322","author":"Monaco","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01222-x_bib105","doi-asserted-by":"crossref","unstructured":"Briani C, Ferrari S, Campagnolo M, Tagliapietra M, Castellani F, Salvalaggio A, et al. Mechanisms of nerve damage in neuropathies associated with hematological diseases: Lesson from nerve biopsies. Brain Sci. 2021;11(2).","DOI":"10.3390\/brainsci11020132"},{"key":"10.1007\/s13311-022-01222-x_bib106","doi-asserted-by":"crossref","unstructured":"Amaador K, Wieske L, Koel-Simmelink MJA, Kamp A, Jongerius I, de Heer K, et al. Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy. J Neurol. 2022.","DOI":"10.1007\/s00415-022-10993-4"},{"key":"10.1007\/s13311-022-01222-x_bib107","doi-asserted-by":"crossref","unstructured":"Doets AY, Hughes RA, Brassington R, Hadden RD, Pritchard J. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2020;1:CD008630.","DOI":"10.1002\/14651858.CD008630.pub5"},{"key":"10.1007\/s13311-022-01222-x_bib108","doi-asserted-by":"crossref","unstructured":"Ruck T, Nimmerjahn F, Wiendl H, Lunemann JD. Next generation antibody-based therapies in neurology. Brain. 2021.","DOI":"10.1093\/brain\/awab465"},{"issue":"9","key":"10.1007\/s13311-022-01222-x_bib109","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41573-019-0031-6","article-title":"Clinical promise of next-generation complement therapeutics","volume":"18","author":"Mastellos","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1007\/s13311-022-01222-x_bib110","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2015.03.005","article-title":"Antagonistic human FcgammaRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo","volume":"27","author":"Roghanian","year":"2015","journal-title":"Cancer Cell"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01222-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01222-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01222-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:56:53Z","timestamp":1761807413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1878747923011091"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01222-x","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01222-x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}